Can I Take Vitamin D with Jatenzo?

What Is Jatenzo and Why Does Vitamin D Come Up?

Jatenzo is the first FDA-approved oral softgel capsule containing testosterone undecanoate, cleared in March 2019 for adult men with primary or hypogonadal hypogonadism [1]. Each capsule is absorbed via intestinal lymphatic transport, bypassing first-pass hepatic metabolism. Doses start at 158 mg twice daily with food and are titrated based on total testosterone levels drawn 6 hours post-dose.

Vitamin D comes up in this context for two reasons. First, testosterone and vitamin D share a well-documented bidirectional relationship in male physiology. Second, men with hypogonadism tend to have lower 25-hydroxyvitamin D (25(OH)D) concentrations than eugonadal men, independent of lifestyle factors [2].

Why Men on TRT Are Often Vitamin D Insufficient

A cross-sectional analysis of 2,299 men in the National Health and Nutrition Examination Survey found that low testosterone correlated with lower 25(OH)D even after adjusting for BMI, season, and physical activity [3]. The mechanism likely involves androgen receptor signaling in the kidney upregulating CYP27B1, the enzyme that converts 25(OH)D to its active form 1,25-dihydroxyvitamin D [4].

That relationship means starting Jatenzo may shift vitamin D metabolism slightly, not enough to cause toxicity but enough to make baseline 25(OH)D testing clinically worthwhile.

Jatenzo's Absorption Pathway

Because Jatenzo relies on lymphatic chylomicron transport, it must be taken with a meal containing fat. Vitamin D (cholecalciferol or ergocalciferol) is also fat-soluble and absorbs more reliably with dietary fat [5]. Taking both at the same fatty meal is therefore logical and does not create competition for absorption sites.

Pharmacokinetic Interaction: Is There One?

No clinically meaningful pharmacokinetic interaction exists between oral testosterone undecanoate and vitamin D. The two compounds travel through entirely different enzymatic routes.

Testosterone is hydroxylated primarily by hepatic CYP3A4 and to a lesser extent CYP2C19. Vitamin D undergoes 25-hydroxylation via CYP2R1 in the liver, then 1-alpha-hydroxylation via CYP27B1 in the kidney, and catabolism via CYP24A1 [6]. None of these enzymes overlap with the primary CYP3A4 pathway for testosterone.

No Shared CYP Pathway

The FDA prescribing information for Jatenzo lists CYP3A4 inducers and inhibitors as potential interaction partners. Cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) do not inhibit or induce CYP3A4 at supplemental doses up to 10,000 IU/day [7]. Published interaction databases, including the Natural Medicines Comprehensive Database, classify the testosterone-vitamin D combination as having no known pharmacokinetic interaction.

Protein Binding: A Minor Theoretical Point

Both testosterone and 25(OH)D bind to vitamin D-binding protein (DBP) and sex hormone-binding globulin (SHBG) at different sites and with different affinities. There is no published clinical evidence that co-administration alters free testosterone or free 25(OH)D concentrations in meaningful ways [8].

Pharmacodynamic Overlap on Bone and Calcium

The area requiring the most attention is not pharmacokinetics. It is the shared downstream effect on calcium and bone mineral density.

Testosterone and vitamin D both stimulate osteoblast activity and suppress osteoclast-driven bone resorption [9]. When both are replaced simultaneously in a deficient man, bone turnover markers can shift faster than with either agent alone.

Calcium and PTH Monitoring

Vitamin D supplementation raises intestinal calcium absorption. Testosterone replacement independently reduces parathyroid hormone (PTH) by about 10 to 15% in hypogonadal men over 12 months, as shown in a 12-month randomized controlled trial by Lerchbaum et al. (N=100) [10]. Combining both agents without monitoring serum calcium is therefore not ideal.

The Endocrine Society's 2018 testosterone therapy guideline states: "We recommend measuring hematocrit, PSA, and bone mineral density at baseline and periodically thereafter in men receiving testosterone therapy" [11]. Serum calcium is not explicitly listed but follows logically from combined vitamin D and testosterone use.

Aim to keep serum calcium at or below 10.2 mg/dL in men supplementing vitamin D on Jatenzo. Readings above 10.5 mg/dL warrant stopping vitamin D until calcium normalizes.

Bone Density: Evidence That Both Help

A 2017 meta-analysis published in the Journal of Clinical Endocrinology and Metabolism (21 RCTs, N=1,083) found that testosterone replacement in hypogonadal men increased lumbar spine BMD by a mean of 5.8% over 24 months [9]. Vitamin D alone added roughly 1 to 2% per year in deficient older men per a 2019 Cochrane review [12]. Whether the effects are purely additive in TRT patients requires further study, but no trial has shown harm from the combination.

Dosing Guidance: How Much Vitamin D to Take with Jatenzo

The Endocrine Society's 2011 vitamin D guideline recommends 1,500 to 2,000 IU/day cholecalciferol for adults at risk of deficiency and 6,000 to 10,000 IU/day for treatment of documented deficiency (25(OH)D below 20 ng/mL), with a target maintenance level of 40 to 60 ng/mL [13].

For most men starting Jatenzo, 2,000 IU cholecalciferol daily is a reasonable starting supplement dose while awaiting baseline 25(OH)D results.

A Practical Tiered Approach

• 25(OH)D 30 to 60 ng/mL (sufficient): 1,000 to 2,000 IU/day cholecalciferol as maintenance.
• 25(OH)D 20 to 29 ng/mL (insufficient): 2,000 to 4,000 IU/day for 12 weeks, then recheck.
• 25(OH)D below 20 ng/mL (deficient): 6,000 IU/day for 8 weeks (or a single 50,000 IU ergocalciferol weekly for 8 weeks), then step down to 2,000 IU/day maintenance.
• Serum calcium above 10.5 mg/dL at any point: Hold vitamin D, recheck calcium in 4 weeks.

This tiered framework aligns with the Endocrine Society clinical practice guideline and adds practical boundaries for men on Jatenzo specifically [13].

Timing with Jatenzo Doses

Jatenzo must be taken twice daily with food. Because vitamin D absorption improves with fat-containing meals [5], taking one vitamin D capsule with the morning Jatenzo dose is convenient and effective. No dose separation window is required.

Monitoring Labs: What to Check and When

Monitoring on Jatenzo already includes total testosterone (6-hour post-dose trough on day 14 or after dose change), hematocrit, PSA, and lipids per the FDA prescribing information [1]. Adding vitamin D-related labs requires modest extra effort.

Recommended Lab Schedule

At Jatenzo initiation:

• Serum 25(OH)D
• Serum calcium and albumin (to calculate corrected calcium)
• iPTH (optional; useful baseline if osteoporosis is a concern)

At 3 months:

• Serum 25(OH)D (to confirm vitamin D dosing is adequate)
• Serum calcium

At 6 to 12 months:

• Repeat the full panel
• DXA scan if baseline BMD was low or the patient has fracture risk factors (FRAX score above 10% for major osteoporotic fracture)

These intervals match standard practice outlined in the American Association of Clinical Endocrinology (AACE) hypogonadism guidelines [14].

When to Involve a Specialist

Persistent hypercalcemia above 10.5 mg/dL despite stopping vitamin D suggests an underlying cause such as primary hyperparathyroidism or a granulomatous disease. Those cases need endocrinology referral regardless of Jatenzo use.

What Clinical Trials Say About Testosterone and Vitamin D Together

Few large randomized trials have specifically enrolled men on oral testosterone undecanoate and co-administered vitamin D. Most evidence comes from injectable testosterone studies or observational cohorts.

Key Trial Data

The TRAVERSE trial (N=5,246 men, mean age 65.6 years, 24-month follow-up) evaluated cardiovascular outcomes of testosterone replacement and included extensive metabolic monitoring [15]. Vitamin D status was not a primary endpoint, but baseline 25(OH)D was measured. Approximately 42% of enrolled men had 25(OH)D below 30 ng/mL at randomization, consistent with the broader hypogonadal male population seen in clinical practice.

A 2013 study by Pilz et al. (N=165 men, 12-month RCT) found that 3,332 IU/day vitamin D3 increased total testosterone from a mean of 10.7 nmol/L to 13.4 nmol/L vs. No change in placebo (P<0.001) [16]. That 25% testosterone increase suggests vitamin D and testosterone therapy may work synergistically on the HPG axis, though the effect size in already-treated hypogonadal men receiving Jatenzo is less clear.

The landmark STEP-1 trial [17] and similar GLP-1 datasets are not directly applicable to Jatenzo, but they underscore that metabolic hormone interactions require prospective study. The Pilz et al. Finding has not yet been replicated at scale in a Jatenzo-specific cohort.

Observational Evidence from NHANES

Analysis of NHANES 2001 to 2010 data (N=3,369 men) showed that men in the lowest quartile of 25(OH)D had a 2.1-fold higher odds of low testosterone compared with men in the highest quartile, after adjustment for age, BMI, and race [3]. This association does not prove causation but does support routine 25(OH)D screening in men presenting with hypogonadism.

Special Populations: Obesity and Older Men

Jatenzo's prescribing information notes that doses may need to be higher in obese men because of altered pharmacokinetics [1]. Obesity also independently reduces 25(OH)D bioavailability, as vitamin D is sequestered in adipose tissue and is less available in circulation [18].

Dose Adjustments in Obesity

A man with a BMI above 35 kg/m2 starting Jatenzo may need 3,000 to 4,000 IU/day vitamin D to achieve the same serum 25(OH)D response as a lean man taking 2,000 IU/day. The Endocrine Society guideline specifically states that obese individuals may require 2 to 3 times the standard replacement dose [13].

Older men (above age 65) have reduced skin synthesis of vitamin D3 and often have concurrent calcium malabsorption. For this group, combined vitamin D3 plus calcium carbonate 500 to 1,000 mg/day is reasonable, provided dietary calcium intake is accounted for to avoid exceeding 2,500 mg/day total (the Tolerable Upper Intake Level set by the Institute of Medicine) [19].

Safety Summary: What You Can Tell Your Prescriber

Taking vitamin D alongside Jatenzo is safe and often beneficial. The combination carries no pharmacokinetic interaction risk. The pharmacodynamic overlap on calcium and bone metabolism is a reason to monitor, not a reason to avoid.

Three points to communicate to your prescriber when starting or continuing vitamin D on Jatenzo:

1. Request a baseline serum 25(OH)D and serum calcium before or at the time of your first Jatenzo prescription.
2. Share your current vitamin D supplement dose and any calcium supplements you take.
3. Ask for a repeat 25(OH)D at your 3-month Jatenzo dose-check visit so adjustments can be made together.

The American Urological Association's 2022 hypogonadism guideline supports screening for and treating comorbid nutritional deficiencies alongside testosterone therapy [20].